This chromosome abnormality, coupled to the short isoform of BCR-ABL1, results in progression to CML-AP, deficiency of response to imatinib, and the necessity for a third generation TKI [73]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.